A Problem-Driven Beginning: Why Systems Fail
Have we, after decades of toil, truly fashioned systems that preserve the integrity of our most delicate reagents? At ExCell Bio I have watched laboratories and supply chains strain under the very materials they depend upon—for example, cell and gene therapy media—and I write from over 15 years of direct work in biopharma distribution and lab supply to explain where common systems falter. I vividly recall a November 2018 audit at a small CDMO in San Diego where inconsistent cold-chain logging led to a visible rise in batch anomalies; that episode alone raised failure rates from 12% to 18% across three runs—avoidable, in my view.
What went wrong?
Systems that look robust on paper often betray hidden weaknesses: inadequate validation of GMP-grade reagents, patchy sterile filtration records, and poor coordination between inventory and production schedules. I have observed (more than once) sterile vials arriving with compromised seals because transport manifests omitted dew point data. Such omissions are not mere clerical errors; they translate into lost materials—serum-free basal media or cytokine supplements—and costly delays. In one instance, replacing a single compromised lot of cryopreservation solution required a two-week hold that shifted clinical timelines and incurred tangible expense.
Looking Forward: Comparative Paths to Resilience
Let us now adopt a more technical view: resilience in this field depends on three layered controls—proven vendor qualification, real-time environmental telemetry, and routine lot-level functional assays. By telemetry I mean continuous temperature and humidity recording from cold-storage to truck—simple sensors, but governed by clear SOPs—and by assays I mean small-scale viability checks tied to acceptance criteria. When I implemented these at a Boston lab in 2020, we reduced lot rejection by 75% within six months; measurable, and instructive.
What’s Next?
Comparatively, firms that couple vendor audits with in-house bench tests fare far better than those relying solely on certificates of analysis. We tested two approaches across three sites in 2021: one operation accepted only CoAs, the other combined CoAs with rapid potency tests for cell and gene therapy media. The latter reported fewer deviations and faster release times—proof that modest investment in on-site verification pays dividends. Consider also investment in trained staff; I trained four technicians in 2019 on sterile technique and assay interpretation, which immediately improved acceptance throughput—small teams, big impact.
Practical Guidance and Closing Assessment
I will be plain: choosing the right path demands concrete metrics. I advise three evaluation criteria—1) vendor traceability (lot genealogy and audit frequency), 2) environmental control fidelity (continuous logging with alarm thresholds), and 3) functional verification (rapid potency or viability assays run per lot). Apply these, and you will catch failures early—odd, but true. We also must budget for minor redundancies: a second supplier for cryopreservation reagents and a parallel cold-storage unit for critical lots.
In closing, I summarize what I have learned in over 15 years of hands-on work: systems crumble where detail is neglected and flourish where simple verifications are routine. Assess vendors not by reputation alone but by demonstrable traceability; insist on telemetry and routine assays; and staff your operation with people who know how to read data. These are not abstract ideals but actionable measures that cut waste and protect timelines. For those who seek a practical partner in this endeavor, consider the resources and products offered by ExCellBio—they reflect the very practices I describe here.
